Previous Close | 10.31 |
Open | 10.47 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's Range | 10.25 - 10.98 |
52 Week Range | 4.81 - 14.40 |
Volume | |
Avg. Volume | 66,952 |
Market Cap | 224.594M |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.54 |
Earnings Date | May 15, 2023 - May 19, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.67 |
/ Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2022 and other recent business developments.
/ Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2022 after the stock market close on Thursday, March 23, 2023. Management will host a webcast/teleconference the same day at 4:30 p.m.